Advertisement

Somatostatin-like immunoreactivity and neurotransmitter metabolites in the cerebrospinal fluid of patients with senile dementia of Alzheimer type and Parkinson’s disease

  • M. Strittmatter
  • H. Cramer
  • C. Reuner
  • D. Strubel
  • F. Kuntzmann
Part of the Key Topics in Brain Research book series (KEYTOPICS)

Summary

The concentration of somatostatin-like immunoreactivity (SLI), the molecular forms of SLI, serotonin and dopamine metabolites in cerebrospinal fluid of patients with senile dementia of Alzheimer type (SDAT), Parkinson’s disease (PD) and age-matched control patients were determined by reverse phase HPLC and by specific radioimmunoassay. The mean SLI level in the control group was 29.5 ± 8.9 fmol/ml. In SDAT and PD the mean SLI level was significantly lower (18.6 7.9 fmol/ml, 21.4 ± 8.1 fmoI/ml). HPLC separation of SLI yielded four peaks with a preponderance of Somatostatin-14 (SST-14) and Somatostatin-28 (SST-28). In SDAT and PD changes in the molecular pattern of somatostatin indicate an altered biosynthesis and/or processing of somatostatin.

Keywords

Alzheimer Type Senile Dementia Dopamine Metabolite Global Deterioration Scale Neurotransmitter Metabolite 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agid Y, Javoy-Agid F (1985) Peptides and Parkinson’s disease. Trends Neurosci 8: 30–35CrossRefGoogle Scholar
  2. Beal MF, Mazurek MF, Mc Black PL, Martin JB (1985) Human cerebrospinal fluid somatostatin in neurological disease. J Neurol Sci 71: 91–104PubMedCrossRefGoogle Scholar
  3. Beal MF, Growdon JH, Mazurek MJ, Martin JB (1986) CSF somatostatin-like immunoreactivity in dementia. Neurology 36: 294–297PubMedCrossRefGoogle Scholar
  4. Cramer H, Schaudt D, Rissler K, Strubel D, Warter JM, Kuntzmann F (1985) Somatostatin-like immunoreactivity and substance P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multiinfarct syndrome and communicating hydrocephalus. J Neurol 232: 346–351PubMedCrossRefGoogle Scholar
  5. Cramer H, Rissler K, Rösler N, Strubel D, Schaudt D, Kuntzmann F (1989) lmmunoreactive substance P and somatostatin in the cerebrospinal fluid of senile parkinsonian patients. Eur Neurol 29: 1–5Google Scholar
  6. Cross AJ, Crow TJ, Perry EK, Blessed G, Tomlinson BE (1981) Reduced dopamine-beta-hydroxylase activity in Alzheimer’s disease. Br Med J 282: 93 — 94Google Scholar
  7. Davies P, Terry RD (1980) Cortical somatostatin-like immunoreactivity in cases of Alzheimer’s disease and senile dementia of the Alzheimer type. Brain Res 171: 319–327CrossRefGoogle Scholar
  8. Dupont E, Christensen SE, Hansen AP, Olivarius BF, Orskow H (1982) Low cerebrospinal fluid somatostatin in Parkinson’s disease: an irreversible abnormality. Neurology 32: 312–314PubMedCrossRefGoogle Scholar
  9. Garcia-Sevilla JA, Athee L, Magnusson T, Carlsson A (1978) Opiate-receptor mediated changes in monoamine synthesis in rat brain. Pharm Pharmacol 30: 613–621CrossRefGoogle Scholar
  10. Hoehn M, Yahr MD (1967) Parkinsonism. Onset, progression, and mortality. Neurology 17: 427–444Google Scholar
  11. Kronheim S, Berelowitz M, Pimstone BL (1977) The presence of immunoreactive growth hormone release-inhibiting hormone in normal cerebrospinal fluid. Clin Endocrinol 6: 411–415CrossRefGoogle Scholar
  12. McGeer PL, McGeer EG, Suzuki J, Dolman CE, Nagai T (1984) Aging, Alzheimer’s disease and the cholinergic system of the basal forebrain. Neurology 34: 741–745Google Scholar
  13. Morrison JH, Rogers J, Scherr S, Benoit R, Bloom FE (1985) Somatostatin immunoreactivity in neuritic plaques of Alzheimer patients. Nature 314: 9092CrossRefGoogle Scholar
  14. Nakamura S, Kshimura K, Kato T, Yamao S, Iijima S, Nagata H, Miyata S, Fujiyoshi K (1984) Neurotransmitters in dementia. Clin Ther 7: 18–34PubMedGoogle Scholar
  15. Oram JJ, Edwardson J, Millard PH (1981) Investigation of cerebrospinal fluid neuropeptides in idiopathic senile dementia. Gerontology 27: 216–223PubMedCrossRefGoogle Scholar
  16. Pierotti AR, Harmar AJ, Simpson J, Yates CM (1985) High-molecular weight forms of somatostatin are reduced in Alzheimer’s disease and Down’s syndrome. Neurosci Lett 63: 141–146CrossRefGoogle Scholar
  17. Reisberg B, Ferris SH, Mony D, De Leon J, Crook T (1982) The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 139: 1136–1139PubMedGoogle Scholar
  18. Rissler K, Cramer H, Schaudt D, Strubel D, Gattaz WF (1986) Molecular size distribution of somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with degenerative brain disease. Neurosci Res 3: 213–225PubMedCrossRefGoogle Scholar
  19. Roberts GW, Crow TJ, Polak JM (1985) Location of neuronal tangles in somatostatin neurones in Alzheimer’s disease. Nature 314: 92–94PubMedCrossRefGoogle Scholar
  20. Soininen H, Jolkkonen JT, Keinikainen KJ, Halonen TO, Riekkinen PJ (1984) Reduced cholinesterase activity and somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Sci 63: 167–172PubMedCrossRefGoogle Scholar
  21. Soerensen KV, Christensen SE, Hansen AP, Ingerslev J, Pedersen E, Orskov H (1981) The origin of cerebrospinal fluid somatostatin: hypothalamic or disperse central nervous system secretion. Neuroendocrinology 32: 335–338CrossRefGoogle Scholar
  22. Terry RD, Davies P (1980) Dementia of the Alzheimer type. Ann Rev Neurosci 3: 77–85PubMedCrossRefGoogle Scholar
  23. Whitehouse PJ, Unnerstall JR (1988) Neurochemistry of dementia. Eur Neurol 28 (1): 36–41PubMedGoogle Scholar
  24. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR (1982) Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 215:1237 —1239Google Scholar
  25. Wood PL, Etienne P, Lal S, Gauthier S, Cajal S, Nair NP (1982) Reduced lumbar CSF somatostatin in Alzheimer’s disease. Life Sci 31: 2073–2079PubMedCrossRefGoogle Scholar
  26. Zubenko GS, Marquis JK, Volicier L, Direnfeld LK, Langlais PJ, Noxin RA (1986) Cerebrospinal fluid levels of angiotensin-converting enzyme, acetyl-cholinesterase, and dopamine metabolites in dementia associated with Alzheimer’s disease and Parkinson’s disease: a correlative study. Biol Psychiatry 21: 1365–1381PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1990

Authors and Affiliations

  • M. Strittmatter
    • 1
  • H. Cramer
    • 1
  • C. Reuner
    • 1
  • D. Strubel
    • 2
  • F. Kuntzmann
    • 2
  1. 1.Department of Neurology and Clinical NeurophysiologyUniversity of FreiburgFederal Republic of Germany
  2. 2.Department of GeriatricsUniversity of StrasbourgFrance

Personalised recommendations